Show simple item record

dc.contributor.author Szigeti, Andrea
dc.contributor.author Ecsedy, Mónika
dc.contributor.author Schneider, Miklós
dc.contributor.author Lénárt, Lilla
dc.contributor.author Lesch, Balázs
dc.contributor.author Nagy, Zoltán Zsolt
dc.contributor.author Fekete, Andrea
dc.contributor.author Récsán, Zsuzsanna
dc.date.accessioned 2017-06-21T08:32:21Z
dc.date.available 2017-06-21T08:32:21Z
dc.date.issued 2016
dc.identifier 84994713291
dc.identifier.citation pagination=e0166544, pages 11; journalVolume=11; journalIssueNumber=11; journalTitle=PLOS ONE;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/4418
dc.identifier.uri doi:10.1371/journal.pone.0166544
dc.description.abstract BACKGROUND: Stromal cell-derived factor 1 (SDF1) has crucial role in the regulation of angiogenesis and ocular neovascularisation (NV). The purpose of this study was to evaluate the association between SDF1-3'G(801)A polymorphism and NV complications of retinal vein occlusion (RVO). METHODS: 130 patients with RVO (median age: 69.0, range 35-93 years; male/female- 58/72; 55 patients had central RVO, 75 patients had branch RVO) were enrolled in this study. In the RVO group, 40 (30.8%) patients were diagnosed with NV complications of RVO and 90 (69.2%) patients without NVs. The median follow up period was 40.3 months (range: 18-57 months). The SDF1-3'G(801)A polymorphism was detected by PCR-RFLP. Allelic prevalence was related to reference values obtained in the control group consisted of 125 randomly selected, age and gender matched, unrelated volunteers (median age: 68.0, range 36-95 years; male/female- 53/72). Statistical analysis of the allele and genotype differences between groups (RVO patients vs controls; RVO patients with NV vs RVO patients without NV) was determined by chi-squared test. P value of <0.05 was considered statistically significant. RESULTS: Hardy-Weinberg criteria was fulfilled in all groups. The SDF1-3'G(801)A allele and genotype frequencies of RVO patients were similar to controls (SDF1-3'A allele: 22.3% vs 20.8%; SDF1-3'(801)AA: 5.4% vs 4.8%, SDF1-3'(801)GG: 60.8% vs 63.2%). The frequency of SDF1-3'(801)AA and SDF1-3'(801)GA genotypes, as well as the SDF1-3'(801)A allele frequency were higher in RVO patients with NV versus in patients without NV complication (SDF1-3'(801)AA+AG genotypes: 57.5% vs 31.1%, p = 0.008; SDF1-3'(801)A allele: 35.0% vs 16.7%, p = 0.002) or versus controls (SDF1-3'(801)AA+AG genotypes 57.5% vs 36.8%, p = 0.021; SDF1-3'(801)A allele: 35.0% vs 20.8% p = 0.01). Carrying of SDF1-3'(801)A allele increased the risk of neovascularisation complications of RVO by 2.69 (OR, 95% CI = 1.47-4.93). CONCLUSION: These findings suggest that carrying SDF1-3'(801)A allele plays a role in the development of neovascular complications in retinal vein occlusion.
dc.relation.ispartof urn:issn:1932-6203
dc.title Stromal Cell-Derived Factor 1 Polymorphism in Retinal Vein Occlusion
dc.type Journal Article
dc.date.updated 2017-06-19T10:20:38Z
dc.language.rfc3066 en
dc.identifier.mtmt 3147786
dc.identifier.wos 000387725000134
dc.identifier.pubmed 27832196
dc.contributor.department SE/AOK/K/Szemészeti Klinika
dc.contributor.department SE/AOK/K/ISZGYK/MTA-SE Lendület Diabétesz Kutatócsoport
dc.contributor.institution Semmelweis Egyetem


Files in this item

This file is available only from Semmelweis network

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account